Antitumour necrosis factor therapy in Crohn’s disease

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.2, Iss.7, 2002-10, pp. : 715-721

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Infliximab use in Crohn’s disease

By Bewtra Meenakshi Lichtenstein Gary R

Expert Opinion on Biological Therapy, Vol. 5, Iss. 4, 2005-04 ,pp. : 589-599

Informa Healthcare

Access to resources Recommend Favorite

Biological response modifiers for the treatment of Crohn’s disease

By Siveke J Folwaczny C

Expert Opinion on Biological Therapy, Vol. 4, Iss. 11, 2004-11 ,pp. : 1719-1727

Informa Healthcare

Access to resources Recommend Favorite

A comparative analysis of the molecular genetic processes in the pathogenesis of psoriasis and Crohn’s disease

By Piruzian E. Ishkin A. Nikol’skaya T. Abdeev R. Bruskin S.

Molecular Biology, Vol. 43, Iss. 1, 2009-02 ,pp. : 159-165

MAIK Nauka/Interperiodica

Access to resources Recommend Favorite

Occupational health and safety of anti-tumour necrosis factor alpha monoclonal antibodies with casual exposure

By Chang Jeff Leong Rupert WL

Expert Opinion on Biological Therapy, Vol. 14, Iss. 1, 2014-01 ,pp. : 27-36

Informa Healthcare

Access to resources Recommend Favorite

Remestemcel-L: human mesenchymal stem cells as an emerging therapy for Crohn's disease

By Mannon Peter J

Expert Opinion on Biological Therapy, Vol. 11, Iss. 9, 2011-09 ,pp. : 1249-1256

Informa Healthcare

Access to resources Recommend Favorite